Amarin (AMRN) to Release Earnings on Wednesday

Amarin (NASDAQ:AMRN) is expected to issue its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($1.27) per share and revenue of $50.6190 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:00 AM ET.

Amarin Stock Up 0.3%

Shares of AMRN opened at $15.63 on Tuesday. The firm has a market cap of $324.95 million, a price-to-earnings ratio of -6.28 and a beta of 0.84. The company’s fifty day moving average is $14.76 and its 200-day moving average is $15.77. Amarin has a 12 month low of $7.08 and a 12 month high of $20.90.

Institutional Investors Weigh In On Amarin

Several hedge funds have recently made changes to their positions in AMRN. Jones Financial Companies Lllp increased its stake in Amarin by 449,522.1% during the first quarter. Jones Financial Companies Lllp now owns 1,811,977 shares of the biopharmaceutical company’s stock valued at $815,000 after acquiring an additional 1,811,574 shares during the period. Millennium Management LLC grew its holdings in shares of Amarin by 25.6% during the 4th quarter. Millennium Management LLC now owns 166,235 shares of the biopharmaceutical company’s stock worth $2,320,000 after purchasing an additional 33,844 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Amarin by 15.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 87,366 shares of the biopharmaceutical company’s stock worth $1,431,000 after purchasing an additional 11,425 shares in the last quarter. Two Sigma Investments LP increased its position in shares of Amarin by 1.8% during the third quarter. Two Sigma Investments LP now owns 60,071 shares of the biopharmaceutical company’s stock valued at $984,000 after purchasing an additional 1,047 shares during the period. Finally, Jump Financial LLC acquired a new position in shares of Amarin in the second quarter valued at $623,000. Institutional investors own 22.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amarin in a report on Wednesday, January 21st. Zacks Research downgraded Amarin from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 27th. Finally, Wall Street Zen lowered Amarin from a “strong-buy” rating to a “buy” rating in a report on Friday, November 28th. Three research analysts have rated the stock with a Sell rating, According to MarketBeat.com, Amarin presently has an average rating of “Strong Sell” and an average target price of $12.00.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.